白蛋白紫杉醇复治Ⅳ期非小细胞肺癌的临床疗效被引量：5

Efficacy of abraxane in the treatment of stage Ⅳ non-small cell lung cancer after failure of multi- line chemotherapy

在线阅读下载PDF

导出

摘要目的:评价白蛋白紫杉醇(nab-p)复治Ⅳ期非小细胞肺癌(NSCLC)的近期疗效和安全性。方法:回顾分析28例使用nab-p单药化疗的Ⅳ期NSCLC患者,其经过一线或一线以上的抗肿瘤治疗后疾病进展,随后接受nab-p 130mg/m2d1、d8,21天为1周期方案,观察近期疗效、无进展生存期(PFS)及毒性反应,并对病理类型及年龄进行亚组分析。结果:28例患者中,CR 0例(0%),PR 6例(21.4%),SD 13例(46.4%),PD 9例(32.1%),ORR 21.4%,DCR 67.9%,中位PFS 4.2个月。主要的III级毒性包括中性粒细胞减少(17.9%),周围神经毒性(3.57%)及血小板减少(3.57%),出现1例Ⅳ度骨髓抑制。鳞癌患者的ORR(23.1%vs 20.0%,P=0.843)及中位PFS(4.6 vs 4.2个月,P=0.433)较非鳞癌有提高趋势。老年肺癌患者的ORR为22.2%,DCR为66.7%,中位PFS为4.2个月,疗效优且耐受性佳。结论:nab-p复治Ⅳ期NSCLC显示出较好的疗效,毒副作用可耐受,肺鳞癌可能能更好的从nab-p中获益,对老年患者高效低毒,值得进一步进行大样本研究。 Objective： To evaluate the short- term efficacy and safety of abraxane in the treatment of stage Ⅳ non- small cell lung cancer（ NSCLC）. Methods： To retrospectively analyze 28 cases of stage Ⅳ NSCLC who had progressed from at least one standard anti- tumor therapy and then followed by monotherapy of abraxane at 130 mg / m^2 every three weeks on day 1,day 8. We assessed the short- term effect and safety as well as treatment associated progress free survival（ PFS） of these patients,also subgroup analysis of pathological type and age were carried out. Results： Among the 28 patients,CR was 0（ 0%）,PR was 6（ 21. 4%）,SD was 13（ 46. 4%）,PD was 9（ 32. 1%）,the ORR was 21. 4%,and the disease control rate（ DCR） was 67. 9%,the PFS was 4. 2 months（ 95% CI： 2. 8 - 6. 5months）. The main grade Ⅲ side effects were neutropenia（ 17. 9%）,peripheral nerve damage（ 3. 57%）,thrombocytopenia（ 3. 57%）,only 1 patient developed stage IV bone marrow suppression. The ORR in squamous lung cancer vs non- squamous NSCLC was 23. 1% vs 20. 0%（ P = 0. 843）,and the PFS was 4. 6 vs 4. 2 months（ P = 0. 433）.Among the elderly patients,the ORR and DCR was 22. 2% and 66. 7% respectively with a good therapeutic effect and tolerance. Conclusion： Abraxane shows a good efficacy in the treatment of previously treated stage Ⅳ NSCLC and well tolerated. Investigation of abraxane in larger samples is worthy due to its prominent therapeutic effect in squamous lung cancer and elder patients.

作者夏莹子凌扬

机构地区苏州大学附属常州肿瘤医院

出处《现代肿瘤医学》 CAS 2016年第22期3559-3563,共5页 Journal of Modern Oncology

关键词非小细胞肺癌白蛋白紫杉醇复治近期疗效安全性 non-small cell lung cancer nanoparticle albumin-bound paclitaxel retreatment short-term efficacy safety

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1邢镨元,李峻岭,石远凯.苹果酸舒尼替尼治疗多次复发的晚期非小细胞肺癌疗效与安全性分析[J].中国肺癌杂志,2013,16(10):519-523. 被引量：11
2陈秀,任胜祥,李雪飞,李嘉瑜,任睿欣,周彩存.白蛋白紫杉醇治疗多线治疗后晚期非小细胞肺癌的疗效分析[J].中国肿瘤临床,2012,29(22):1824-1827. 被引量：18
3Qi Zheng,Yu Yao,Kejun Nan.Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer:a series of 20 cases[J].The Journal of Biomedical Research,2012,26(3):159-164. 被引量：7
4方瑛,王丽,夏国豪,史美祺.白蛋白结合型紫杉醇联合替吉奥作为三线及以上方案治疗晚期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2013,18(12):1131-1134. 被引量：11

二级参考文献78

1Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2Chang A. Chemotherapy, chemoresistance and the chang- ing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3-10.
3Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small-cell lung cancer. Oncologist 1999; 4: 408-16.
4Schiller JH, Harrington D, Belani CP, Langer C, Sandier A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
5Kloover JS, den Bakker MA, Gelderblom H, van Meer- beeck J P. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br J Cancer 2004; 90: 304-5.
6Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cre- mophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-8.
7Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla R J, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
8Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, et al. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977; 7: 63-7.
9Gianni L, Kearns CM, Giani A, Capri G, Vigan6 L, Lac- atelli A, et al. Nonlinear pharmacokinetics and metabo- lism of paclitaxel and its pharmacokinetic/pharmacody-namic relationships in humans. J Clin Oncol 1995; 13: 180-90.
10Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999; 59: 1454-7.